Thursday, December 10, 2015
Parkinson’s patients have some good news: Charles River Laboratories today announced a significant expansion of its work with small molecule LRRK2 inhibitors, funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). [Read More]
Rep. Elijah Cummings (D-Md.), ranking member of the House Committee on Oversight and Government Reform, has sent a letter to former hedge fund manager Martin Shkreli, CEO of Turing Pharmaceuticals, condemning his company’s efforts to tout a 50% “price cut” for Daraprim after the company increased the price of the drug in August by 5,000%.